Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.50 |
| ▸ | MERTK | Q12866 | 7/20 | 0.50 |
| ▸ | AXL | P30530 | 6/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217918 | 0.91 | MERTK (0.53) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217701 | 0.88 | MET (0.51) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217941 | 0.85 | MERTK (0.57) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217905 | 0.84 | MET (0.55) | METMERTKAXLATRMKNK1 | |
| SCHEMBL10217809 | 0.83 | MET (0.50) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217925 | 0.81 | MET (0.57) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217922 | 0.80 | MERTK (0.56) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217500 | 0.80 | MERTK (0.59) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL488613 | 0.80 | MET (0.66) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL30452977 | 0.80 | MET (0.66) | METMERTKAXLAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885MERTK 69/4885AXL 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.